Clinical trial
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In…
NCT00326248 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00326248 |
|---|---|
| Title | Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women |
| Official title | A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Nausea and Vomiting, Postoperative |
| Intervention type | Drug |
| Interventions | GW679769 (casopitant) |
| Enrollment | 482 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | May 16, 2006 |
| Last update posted | Oct 26, 2016 |
| Countries | Canada, France, Germany, Hong Kong, Hungary, Ireland, Pakistan, Philippines, Thailand, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: